ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

January 13, 2006

CCOP RFA Due In Mid-July; DCT Board Gives Its Concept Approval

June 11, 1982

Smokeless Tobacco Consensus Conference Slates in Health Risks

August 16, 1985

Ontak Approved For Lymphoma

October 31, 2008

NCI’s Richard Kaplan named associate director, National Cancer Research Network of UK.

January 2, 2004

In Brief: Lawyers Halt Reference Chemical Distribution To Grantees, Threaten To Stop Viruses, Animals

September 2, 1977